LEXX — Lexaria Bioscience Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1348362 ·
Last close
$3.20
Market Cap
$6.74M
52W High
$21.60
52W Low
$2.77
ADV30
104,966
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | — | — | — | — | — | — | — |
| Feb 2026 | 20,000 | 20,000 | -1,451,903 | -1,449,979 | 6,487,303 | 5,128,141 | 276,997 |
| Nov 2025 | 0 | 0 | -1,573,631 | -1,595,007 | 6,050,807 | 4,281,233 | 1,527,353 |
| Aug 2025 | 174,000 | 174,000 | -2,688,597 | -2,695,838 | 4,175,121 | 1,802,123 | 1,572,366 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,374,421
Investing CF
$-236,329
Financing CF
$8,207,155
CapEx
$-95,063
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-07-19
Balance + Analyst (yfinance extras)
Retained Earnings
$-66,505,599
Inventory
—
Receivables
$42,029
ST Investments
$141,266
EBIT TTM
$-9,464,552
Pretax Income TTM
$-9,533,680
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$194,000
EBITDA
$-7,417,538
Free Cash Flow
$-4,688,228
Enterprise Value
$2,636,051
Total Cash
$3,617,106
Total Debt
$86,714
Shares Out
2,106,487
Trailing EPS
$-5.10
Book Value
$2.87
ROE
-162.8%
ROA
-81.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Aug 2025 | 705,923 | -11,880,737 | -11,901,841 | 4,175,121 | 1,572,366 | 2,989,697 | -10,450,387 |
| Aug 2024 | 464,278 | -5,753,130 | -5,795,345 | 8,867,789 | 1,208,738 | 8,036,400 | -4,959,003 |
| Aug 2023 | 226,208 | -6,534,022 | -6,664,899 | 3,083,986 | 403,908 | 3,044,118 | -5,881,237 |
| Aug 2022 | 255,397 | -6,619,039 | -7,269,324 | 7,833,927 | 201,437 | 7,948,904 | -4,879,339 |
TTM Snapshot
Revenues TTM
$368,000
NetIncome TTM
$-9,529,916
OpCashFlow TTM
—
Assets (Latest)
$6,487,303
Forward EPS
$-0.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRSN | NeuroSense Therapeutics Ltd. | $6.79M | $3.58 | — |
| ENVB | Enveric Biosciences, Inc. | $6.80M | $1.52 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $6.56M | $0.50 | — |
| XCUR | EXICURE, INC. | $6.55M | $1.00 | — |
| ALZN | Alzamend Neuro, Inc. | $6.47M | $1.34 | — |
News headlines (Yahoo Finance, 1h cache)
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
2026-10-06 13:10 · Yahoo
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
2026-09-08 12:00 · Yahoo
LEXX: Introducing DehydraTECH 3.0
2026-09-08 10:15 · Yahoo
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-04 13:20 · Yahoo
Lexaria Receives USD$2.6 Million Tax Rebate Payment
2026-09-01 13:15 · Yahoo
Lexaria Enters a Material Transfer Agreement With PegBio
2026-08-13 13:00 · Yahoo
LEXX: Dosing Started for Animal & Human GLP-1 Studies
2026-07-17 15:54 · Yahoo
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
2026-06-25 13:10 · Yahoo
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
2026-06-23 13:25 · Yahoo
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
2026-06-17 13:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.